跳转至内容
Merck
CN

P-007

PCP(苯环利定)标准液 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

别名:

苯环利定

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C17H25N
化学文摘社编号:
77-10-1
分子量:
243.39
UNSPSC Code:
41116107
PubChem Substance ID:
329820005
NACRES:
NA.24
MDL number:
MFCD00055598

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

SMILES string

N3(CCCCC3)C2(CCCCC2)c1ccccc1

InChI

1S/C17H25N/c1-4-10-16(11-5-1)17(12-6-2-7-13-17)18-14-8-3-9-15-18/h1,4-5,10-11H,2-3,6-9,12-15H2

InChI key

JTJMJGYZQZDUJJ-UHFFFAOYSA-N

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIA (Portugal); Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet, kontrollierte Droge in Deutschland

Quality Level

300

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

2-8°C

相关类别

General description

苯环利啶，通常称为PCP，是一种具有致幻作用和神经毒性作用的娱乐性药物。 PCP具有“天使尘埃”或“wet”之类的街道名称，呈粉末或液体形式。非法形式的药物通常喷雾至多叶材料（例如大麻）上，然后进行抽吸。此认证溶液标准品可作为校准物和对照品中的起始材料，通过LC/MS或GC/MS，用于从法医分析和临床毒理学到尿液药物测试方面的各种应用中。

Legal Information

German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

存储类别

3 - Flammable liquids

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

法规信息

监管及禁止进口产品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Daniel C Javitt
Schizophrenia bulletin, 38(5), 911-913 (2012-09-19)
At present, all medications for schizophrenia function primarily by blocking dopamine D2 receptors. Over 50 years ago, the first observations were made that subsequently led to development of alternative, glutamatergic conceptualizations. This special issue traces the historic development of the
Pritsana Piyabhan et al.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 96(2), 231-238 (2013-08-14)
Cognitive impairment is a common characteristic in schizophrenia that cannot be attenuated by antipsychotics. Brahmi, popularly known as a cognitive enhancer might be a new frontier of cognitive deficit treatment in schizophrenia. To study effects of Brahmi on attenuation at
Bryan L Roth et al.
PloS one, 8(3), e59334-e59334 (2013-03-26)
In this paper we determined the pharmacological profiles of novel ketamine and phencyclidine analogues currently used as 'designer drugs' and compared them to the parent substances via the resources of the National Institute of Mental Health Psychoactive Drug Screening Program.
Min Feng et al.
Behavioural brain research, 238, 178-187 (2012-10-25)
Repeated administration of antipsychotic drugs induces a sensitization-like or tolerance-like effect in many behavioral tasks, including the conditioned avoidance response (CAR) and the phencyclidine (PCP)-induced hyperlocomotion, two rodent models with high predictive validity for antipsychotic activity. This study investigated the
Masakuni Horiguchi et al.
Behavioural brain research, 238, 36-43 (2012-09-29)
Development of dopamine (DA) D(1) receptor agonists is a priority to improve cognitive impairment in schizophrenia (CIS). This study examined the dose-response relationship of the selective D(1) agonist, SKF38393 (0.5-40 mg/kg), to reverse the deficit in novel object recognition (NOR)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持